Note 17 – Share Based Awards (Tables)
|
6 Months Ended |
Oct. 31, 2022 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| [custom:ScheduleOfAssumptionsUsed1TableTextBlock] |
| |
|
|
2022 |
|
|
|
2021 |
|
| Exercise Price |
|
$ |
2.38 |
|
|
$ |
2.41 – 2.60
|
|
| Stock price on date of grant |
|
|
2.38 |
|
|
|
2.41 – 2.60
|
|
| Risk-free interest rate |
|
|
3.34 |
% |
|
|
0.47 – 1.57% |
|
| Dividend yield |
|
|
— |
|
|
|
— |
|
| Expected term (years) |
|
|
8.25 |
|
|
|
3.75 – 10.00 |
|
| Volatility |
|
|
260.06 |
% |
|
|
210.68 – 214.17% |
|
|
| Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block] |
| Options |
|
Shares |
|
Weighted-Average
Exercise Price |
|
Weighted-Average
Remaining Contractual Term |
|
Aggregate
Intrinsic Value |
| Outstanding as of April
30, 2021 |
|
|
2,197,475 |
|
|
$ |
1.79 |
|
|
|
8.68 |
|
|
|
4,943,870 |
|
| Granted |
|
|
1,681,000 |
|
|
|
2.58 |
|
|
|
|
|
|
|
|
|
| Exercised |
|
|
(150,000 |
) |
|
|
2.49 |
|
|
|
|
|
|
|
|
|
| Forfeited
or expired |
|
|
(34,333 |
) |
|
|
2.11 |
|
|
|
|
|
|
|
|
|
| Outstanding as of April
30, 2022 |
|
|
3,694,142 |
|
|
|
2.17 |
|
|
|
8.56 |
|
|
|
1,407,545 |
|
| Granted |
|
|
397,000 |
|
|
|
2.38 |
|
|
|
|
|
|
|
|
|
| Exercised |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Forfeited
or expired |
|
|
(96,584 |
) |
|
|
2.48 |
|
|
|
|
|
|
|
|
|
| Outstanding as of October 31, 2022 |
|
|
3,994,558 |
|
|
|
2.18 |
|
|
|
8.22 |
|
|
|
608,162 |
|
| Exercisable as of
October 31, 2022 |
|
|
2,569,306 |
|
|
$ |
2.06 |
|
|
|
7.48 |
|
|
$ |
559,578 |
|
|
| Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] |
| Restricted Stock |
|
Shares |
|
Weighted Average Grant-Date Fair Value Per Share |
| Unvested and outstanding as of April 30, 2021 |
|
|
687,500 |
|
|
$ |
2.69 |
|
| Granted |
|
|
995,659 |
|
|
|
2.55 |
|
| Vested |
|
|
(599,484 |
) |
|
|
2.64 |
|
| Forfeited |
|
|
— |
|
|
|
— |
|
| Unvested and outstanding as of April 30, 2022 |
|
|
1,083,675 |
|
|
|
2.59 |
|
| Granted |
|
|
696,000 |
|
|
|
2.27 |
|
| Vested |
|
|
(673,161 |
) |
|
|
2.45 |
|
| Forfeited |
|
|
— |
|
|
|
— |
|
| Unvested and outstanding as of October 31, 2022 |
|
|
1,106,514 |
|
|
$ |
2.48 |
|
|
| Schedule of Deferred Compensation Arrangement with Individual, Share-Based Payments [Table Text Block] |
| |
|
|
|
|
|
|
|
|
| |
|
Three months ended October 31,
|
|
Six months ended October 31,
|
| |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
| Operations |
|
$ |
225,879 |
|
|
$ |
311,346 |
|
|
$ |
384,310 |
|
|
$ |
374,607 |
|
| Research and development |
|
|
209,497 |
|
|
|
84,751 |
|
|
|
354,295 |
|
|
|
141,231 |
|
| Sales and marketing |
|
|
162,269 |
|
|
|
114,088 |
|
|
|
269,343 |
|
|
|
158,832 |
|
| General and administrative |
|
|
649,151 |
|
|
|
389,752 |
|
|
|
994,319 |
|
|
|
609,353 |
|
| Total |
|
$ |
1,246,796 |
|
|
$ |
899,937 |
|
|
$ |
2,002,267 |
|
|
$ |
1,284,023 |
|
|